Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment

dc.contributor.authorde Matos, Djamile Cordeiro [UNESP]
dc.contributor.authorAbreu de Ribeiro, Livia Carolina [UNESP]
dc.contributor.authorTansini, Aline [UNESP]
dc.contributor.authorFerreira, Lucas Souza [UNESP]
dc.contributor.authorPolesi Placeres, Marisa Campos [UNESP]
dc.contributor.authorLuis Colombo, Lucas
dc.contributor.authorCarlos, Iracilda Zeppone [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniv Buenos Aires
dc.date.accessioned2014-05-20T13:23:52Z
dc.date.available2014-05-20T13:23:52Z
dc.date.issued2012-07-24
dc.description.abstractBackground: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4(+) and CD8(+) T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 mu g/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.en
dc.description.affiliationSão Paulo State Univ, Clin Immunol Lab, Sch Pharmaceut Sci, São Paulo, Brazil
dc.description.affiliationUniv Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina
dc.description.affiliationUniv Estadual Paulista, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP, Brazil
dc.description.affiliationUnespSão Paulo State Univ, Clin Immunol Lab, Sch Pharmaceut Sci, São Paulo, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Fac Ciencias Farmaceut, BR-14801902 Araraquara, SP, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent6
dc.identifierhttp://dx.doi.org/10.1186/1472-6882-12-107
dc.identifier.citationBmc Complementary and Alternative Medicine. London: Biomed Central Ltd., v. 12, p. 6, 2012.
dc.identifier.doi10.1186/1472-6882-12-107
dc.identifier.fileWOS000310323800001.pdf
dc.identifier.issn1472-6882
dc.identifier.lattes1730146818754269
dc.identifier.urihttp://hdl.handle.net/11449/7269
dc.identifier.wosWOS:000310323800001
dc.language.isoeng
dc.publisherBiomed Central Ltd.
dc.relation.ispartofBMC Complementary and Alternative Medicine
dc.relation.ispartofjcr2.109
dc.relation.ispartofsjr0,858
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectPulchellinen
dc.subjectBreast canceren
dc.subjectCytokinesen
dc.subjectImmune systemen
dc.titleImmunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatmenten
dc.typeArtigo
dcterms.licensehttp://www.biomedcentral.com/about/license
dcterms.rightsHolderBiomed Central Ltd.
unesp.author.lattes1730146818754269
unesp.author.orcid0000-0002-0084-3468[7]
unesp.author.orcid0000-0003-2282-7562[4]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
WOS000310323800001.pdf
Tamanho:
348.6 KB
Formato:
Adobe Portable Document Format
Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: